Disclosures for "OCARINA I, Phase Ib Study: Dose Selection of Subcutaneous Ocrelizumab in Patients with Multiple Sclerosis "
-
Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Greenwich Biosciences. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Newsome has received research support from Biogen. The institution of Dr. Newsome has received research support from Genentech/Roche. The institution of Dr. Newsome has received research support from Department of Defense. The institution of Dr. Newsome has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Newsome has received research support from National MS Society. The institution of Dr. Newsome has received research support from The Stiff Person Syndrome Research Foundation. The institution of Dr. Newsome has received research support from Lundbeck. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving as a Lead PI for Clinical Trial with Roche.
-
Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for biogen. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Goldstick has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for genentech. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for sanofi Aventis genzyme. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for emd serono. Dr. Goldstick has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TGA therapeutics. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for emd serono. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Aventis genzyme. Dr. Goldstick has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for genentech. Dr. Goldstick has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyers Squibb. Dr. Goldstick has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TGA therapeutics. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for biogen. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for bristol meyers squibb. Dr. Goldstick has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for genentech. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for sanofi aventis genzyme. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for emd serono. Dr. Goldstick has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TGA therapeutics. The institution of Dr. Goldstick has received research support from biogen. The institution of Dr. Goldstick has received research support from lily. The institution of Dr. Goldstick has received research support from sanofi Aventis genzyme. The institution of Dr. Goldstick has received research support from genetech.
-
Dr. Townsend has received personal compensation for serving as an employee of F. Hoffmann-La Roche Ltd. Dr. Townsend has received stock or an ownership interest from F. Hoffmann-La Roche Ltd.
-
Mrs. Zecevic has nothing to disclose.
-
Dr. Augustin has received personal compensation for serving as an employee of Roche.
-
Dr. Figueiredo has received personal compensation for serving as an employee of Roche. Dr. Figueiredo has stock in Roche.
-
Susanne Clinch has received personal compensation for serving as an employee of Roche Products Limited. Susanne Clinch has stock in F.Hoffman-La Roche Ltd.
-
Miss Giacobino has received personal compensation for serving as an employee of F. Hoffmann-La Roche Ltd.. Miss Giacobino has stock in F. Hoffmann-La Roche Ltd..
-
Dr. Bortolami has received personal compensation for serving as an employee of Roche. Dr. Bortolami has received personal compensation in the range of $500-$4,999 for serving as a Statistical Reviewer with Emergency Medicine Journal.
-
Ms. Shen has received personal compensation for serving as an employee of Genentech. Ms. Shen has stock in Roche. Ms. Shen has received intellectual property interests from a discovery or technology relating to health care.
-
Heidemarie Kletzl has received personal compensation for serving as an employee of Hoffmann-La Roche.
-
Dr. Bermel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Bermel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viela Bio. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck Serono. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Astra Zeneca. Dr. Bermel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LabCorp. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Bermel has received research support from Biogen. The institution of Dr. Bermel has received research support from Roche. The institution of Dr. Bermel has received research support from Novartis. Dr. Bermel has received intellectual property interests from a discovery or technology relating to health care.